37 min listen
Getting access for patients to new medications in Germany
Getting access for patients to new medications in Germany
ratings:
Length:
54 minutes
Released:
Nov 12, 2018
Format:
Podcast episode
Description
Today, regulatory approval doesn't ensure anymore, that patients benefit from new therapies. As statisticians, we also need to ensure access and reimbursement for new treatments in the different markets around the world.
The process to gain this access and reimbursement in Germany comes with very specific challenges. Yet, due to the large impact of Germany on other countries via the complex reference pricing system and the size of the population of Germany, we must understand these topics.
Andreas Schwenke gathered experiences across therapeutic areas with many companies since the start of the new process in Germany. This makes him the most experienced and best connected statistician in the world for this topic.
The process to gain this access and reimbursement in Germany comes with very specific challenges. Yet, due to the large impact of Germany on other countries via the complex reference pricing system and the size of the population of Germany, we must understand these topics.
Andreas Schwenke gathered experiences across therapeutic areas with many companies since the start of the new process in Germany. This makes him the most experienced and best connected statistician in the world for this topic.
Released:
Nov 12, 2018
Format:
Podcast episode
Titles in the series (100)
Is data science something for you?: Interview with Cytel statisticians Yannis Jemiai and Rajat Mukherjee by The Effective Statistician - in association with PSI